The story of Sildenafil presents a complex case for investors in the medicinal sector. While initially a blockbuster success, creating vast sums, the intellectual property expiration and the subsequent entry of https://pharma390560.blog2learn.com/89388178/the-little-copyright-and-big-pharma-a-hazardous-investment